Patents by Inventor Andre Marozsan

Andre Marozsan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING MYOINTIMAL PROLIFERATION
    Publication number: 20220354933
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Application
    Filed: May 18, 2022
    Publication date: November 10, 2022
    Inventors: Yan YAN, Anumeha SHAH, Ashmita SAIGAL, Herman GRIFFIN, Susan Faas MCKNIGHT, Andre MAROZSAN, Kim ASKEW, Yvonne NITSCHKE, Frank RUTSCH
  • Methods of treating myointimal proliferation
    Patent number: 11364284
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: June 21, 2022
    Assignees: Inozyme Pharma, Inc., Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Yan Yan, Anumeha Shah, Ashmita Saigal, Herman Griffin, Susan Faas McKnight, Andre Marozsan, Kim Askew, Yvonne Nitschke, Frank Rutsch
  • ANTI-ALK2 ANTIBODIES AND USES THEREOF
    Publication number: 20220098310
    Abstract: Provided herein are antibodies that bind to activin receptor—like kinase 2 (ALK2) and are useful for treating bone disorders, such as those involving reduced bone mineral density and bone mineralization defects, and promoting bone growth. Also provided are polynucleotides encoding the antibodies, vectors comprising the polynucleotides, and cells that produce the antibodies.
    Type: Application
    Filed: December 5, 2019
    Publication date: March 31, 2022
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Jeffrey William Hunter, Julian Chandler, Keith Bouchard, Andre Marozsan, Patricia Bento, Anjli Kukreja
  • Treating seizure with recombinant alkaline phosphatase
    Patent number: 11224638
    Abstract: The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: January 18, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Andre Marozsan, Denise Devore, Susan Liu-Chen
  • Treating muscle weakness with alkaline phosphatases
    Patent number: 11186832
    Abstract: The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease, comprising administering to said subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: November 30, 2021
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventor: Andre Marozsan
  • METHODS OF TREATING MYOINTIMAL PROLIFERATION
    Publication number: 20200306349
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 1, 2020
    Inventors: Yan YAN, Anumeha SHAH, Ashmita SAIGAL, Herman GRIFFIN, Susan Faas MCKNIGHT, Andre MAROZSAN, Kim ASKEW, Yvonne NITSCHKE, Frank RUTSCH
  • METHODS OF IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING A RECOMBINANT ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE (NPP1)
    Publication number: 20200263153
    Abstract: The present invention provides methods for improving cardiovascular function in a human patient (e.g., reducing hypertension), as well as methods of treating a cardiovascular disease, by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Application
    Filed: September 26, 2018
    Publication date: August 20, 2020
    Inventors: Tayeba KHAN, Andre MAROZSAN, Kim ASKEW
  • TREATING SEIZURE WITH RECOMBINANT ALKALINE PHOSPHATASE
    Publication number: 20200093898
    Abstract: The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
    Type: Application
    Filed: October 18, 2019
    Publication date: March 26, 2020
    Inventors: Andre MAROZSAN, Denise DEVORE, Susan LIU-CHEN
  • Treating seizure with recombinant alkaline phosphatase
    Patent number: 10449236
    Abstract: The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 22, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Andre Marozsan, Denise Devore, Susan Liu-Chen
  • TREATING MUSCLE WEAKNESS WITH ALKALINE PHOSPHATASES
    Publication number: 20190119659
    Abstract: The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease, comprising administering to said subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 25, 2019
    Inventor: Andre MAROZSAN
  • Materials and methods for producing cleaved, HIV-1 envelope glycoprotein trimers
    Patent number: 10106583
    Abstract: Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of HIV-1 envelope proteins, including SOSIP modified gp140 trimers capable of inducing broadly neutralizing antibodies.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 23, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Andre Marozsan, Albert Cupo, John Moore
  • TREATING SEIZURE WITH RECOMBINANT ALKALINE PHOSPHATASE
    Publication number: 20170360899
    Abstract: The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
    Type: Application
    Filed: December 4, 2015
    Publication date: December 21, 2017
    Inventors: Andre MAROZSAN, Denise DEVORE, Susan LIU-CHEN
  • HIV-1 envelope glycoprotein
    Patent number: 9738688
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: August 22, 2017
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL UNIVERSITY
    Inventors: Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien
  • MATERIALS AND METHODS FOR PRODUCING CLEAVED, HIV-1 ENVELOP GLYCOPROTEIN TRIMERS
    Publication number: 20170015711
    Abstract: Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of HIV-1 envelope proteins, including SOSIP modified gp140 trimers capable of inducing broadly neutralizing antibodies.
    Type: Application
    Filed: March 9, 2015
    Publication date: January 19, 2017
    Inventors: Andre Marozsan, Albert Cupo, John Moore
  • NOVEL HIV-1 ENVELOPE GLYCOPROTEIN
    Publication number: 20140212458
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.
    Type: Application
    Filed: November 5, 2013
    Publication date: July 31, 2014
    Applicants: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL CENTER FOR TECHNOLOGY ENTERPRISE AND COMMERCIALIZATION
    Inventors: Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien